Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
暂无分享,去创建一个
Gudrun Schleiermacher | Jan Koster | Javed Khan | Rogier Versteeg | Isabelle Janoueix-Lerosey | Olivier Delattre | Julie M Gastier-Foster | Trevor J Pugh | Leo Colmet Daage | Virginie Bernard | Angela Bellini | Mathieu Chicard | Eve Lapouble | Sharon J Diskin | Shahab Asgharzadeh | Daniela S Gerhard | John M Maris | D. Gerhard | J. Khan | Jun S. Wei | A. Naranjo | D. Zwijnenburg | T. Pugh | J. Gastier-Foster | O. Delattre | J. Maris | C. V. D. Schoot | R. Versteeg | H. Caron | P. Sluis | S. Diskin | D. Oldridge | J. Koster | V. Bernard | E. Attiyeh | S. Asgharzadeh | Malcolm A. Smith | J. G. Auvil | M. Hogarty | V. Combaret | M. E. Ebus | J. Schulte | J. Molenaar | P. van Sluis | T. Watkins | C. E. van der Schoot | I. Janoueix-Lerosey | G. Tytgat | G. Schleiermacher | L. Schild | E. Lapouble | J. Michon | Shile Zhang | Angela Bellini | Mathieu Chicard | Shile Zhang | Ellen M Westerhout | Johannes H Schulte | Malcolm A Smith | Valérie Combaret | Jean Michon | Patricia Legoix-Né | Lori S. Hart | Huib N Caron | Jaime M Guidry Auvil | Jan J Molenaar | Jun S Wei | Thomas B K Watkins | Lori S Hart | Michael D Hogarty | Peter van Sluis | C Ellen van der Schoot | JulieAnn Rader | M. Dolman | Marli E Ebus | Arlene Naranjo | Jaime M Guidry Auvil | Danny A Zwijnenburg | Edward F Attiyeh | Godelieve A Tytgat | Thomas F Eleveld | Derek A Oldridge | Linda Schild | Nadia Bessoltane Bentahar | Anne Hakkert | Esther van Wezel | M Emmy M Dolman | J. Rader | T. F. Eleveld | Malcolm A. Smith | E. M. Westerhout | N. Bentahar | P. Legoix-né | Anne Hakkert | E. Wezel | T. Pugh | E. V. van Wezel | Nadia Bentahar | P. V. van Sluis | Patricia Legoix-né | Esther M. van Wezel | L. C. Daage | C. E. van der Schoot
[1] Giovanni Parmigiani,et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma , 2012, Nature Genetics.
[2] Jan Koster,et al. NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome , 2010, Cell.
[3] D. Zwijnenburg,et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes , 2012, Nature.
[4] N. Hayward,et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma , 2014, Nature Communications.
[5] J. Maris,et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. , 2013, The Lancet. Oncology.
[6] A. Bouchard-Côté,et al. PyClone: statistical inference of clonal population structure in cancer , 2014, Nature Methods.
[7] R. Arceci. The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report , 2009 .
[8] Z. Szallasi,et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] J. Maguire,et al. Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively Parallel Targeted Sequencing , 2009, Nature Biotechnology.
[10] J. Maris,et al. Children's Oncology Group's 2013 blueprint for research: Neuroblastoma , 2013, Pediatric blood & cancer.
[11] K. Ross,et al. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma , 2014, Oncotarget.
[12] Bandana Sharma,et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. , 2012, Cancer cell.
[13] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[14] Gudrun Schleiermacher,et al. Accumulation of segmental alterations determines progression in neuroblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. McKenna,et al. Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.
[16] R. Arceci. Localized Infant Neuroblastomas Often Show Spontaneous Regression: Results of the Prospective Trials NB95-S and NB97 , 2009 .
[17] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[18] Ravi Radhakrishnan,et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. , 2014, Cancer cell.
[19] Hiroyuki Shimada,et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. , 2005, The New England journal of medicine.
[20] F. Speleman,et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. , 1999, The New England journal of medicine.
[21] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.
[22] A. Olshan,et al. Children's Oncology Group's 2013 blueprint for research: Epidemiology , 2013, Pediatric blood & cancer.
[23] Kenny Q. Ye,et al. An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.
[24] Rogier Versteeg,et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. , 1996, The New England journal of medicine.
[25] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[26] Robert B. Hartlage,et al. This PDF file includes: Materials and Methods , 2009 .
[27] K. Matthay,et al. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. , 2008, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[28] F. Speleman,et al. Emergence of new ALK mutations at relapse of neuroblastoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Jinghui Zhang,et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. , 2012, JAMA.
[30] A. McKenna,et al. Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.
[31] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[32] Thomas Zichner,et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis , 2012, Bioinform..
[33] J. Maris. Recent advances in neuroblastoma. , 2010, The New England journal of medicine.
[34] R. Versteeg,et al. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. , 2012, European journal of cancer.
[35] Steven J. M. Jones,et al. Circos: an information aesthetic for comparative genomics. , 2009, Genome research.
[36] H. Sather,et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.
[37] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[38] R. Foà,et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. , 2006, American journal of human genetics.
[39] Steven J. M. Jones,et al. The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.
[40] Giovanni Parmigiani,et al. Patient-oriented gene set analysis for cancer mutation data , 2010, Genome Biology.
[41] M. Cole,et al. High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma , 2010, Clinical Cancer Research.
[42] D. Gary Gilliland,et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.
[43] F. Berthold,et al. Treatment and outcomes of patients with relapsed, high‐risk neuroblastoma: Results of German trials , 2011, Pediatric blood & cancer.